1–2 of 2 results for complement C5
Avacincaptad Pegol, A Novel C5 Inhibitor, and GATHER1 Study: Results From a Post-Hoc Analysis of Nascent Geographic Atrophy
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD
Baruch D. Kuppermann, MD, PhD
2020